Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bladder Cancer
New bladder cancer research from Medical University of Innsbruck described
April 22nd, 2008
"EpCAM is an adhesion molecule of the basolateral membranes in a variety of epithelial cells. Over-expression has been detected in many epithelial tumours and has been associated with high stage, high grade and a worse survival in some tumour types," scientists writing in the Journal of Clinical Pathology report. "To assess the prognostic value of EpCAM in urothelial carcinoma of the bladder. EpCAM expression was analysed by immunohistochemistry using a monoclonal antibody ( clone VU-1D9) on a tissue microarray comprising 99 urothelial carcinomas of the bladder diagnosed between 1994 and 1997. A significant relationship between high grade, advanced stage, and...
Source: Cancer Weekly (2008-04-22)
|
